Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cidara Therapeutics

46.84
+1.894.20%
Post-market: 45.62-1.2189-2.60%17:18 EDT
Volume:3.47M
Turnover:166.32M
Market Cap:607.51M
PE:-1.75
High:56.83
Open:49.71
Low:43.04
Close:44.95
Loading ...

RBC Cuts Price Target on Cidara Therapeutics to $31 From $34, Keeps Outperform, Speculative Risk

MT Newswires Live
·
09 May

Cidara Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

BRIEF-Cidara Therapeutics Inc Files For Mixed Shelf Of Up To $500 Million - SEC Filing

Reuters
·
09 May

Cidara Therapeutics reports Q1 EPS ($1.66) vs. ($2.28) last year

TIPRANKS
·
09 May

Cidara Therapeutics Inc Files for Mixed Shelf of up to $500 Mln - SEC Filing

THOMSON REUTERS
·
09 May

Cidara Therapeutics Q1 EPS $(1.66) Beats $(2.71) Estimate

Benzinga
·
09 May

Cidara Therapeutics Q1 EPS USD -1.66

THOMSON REUTERS
·
09 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
08 May

Cidara Therapeutics Inc expected to post a loss of $3.54 a share - Earnings Preview

Reuters
·
07 May

Cidara Therapeutics Names Nicole Davarpanah as Chief Medical Officer

MT Newswires Live
·
01 May

Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to Svp, Clinical Development

THOMSON REUTERS
·
01 May

Press Release: Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development

Dow Jones
·
01 May

Are You Looking for a Top Momentum Pick? Why Cidara Therapeutics (CDTX) is a Great Choice

Zacks
·
01 May

Cidara Therapeutics Price Target Maintained With a $46.00/Share by JMP Securities

Dow Jones
·
30 Apr

Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025

GlobeNewswire
·
24 Apr

Cidara Therapeutics Price Target Maintained With a $35.00/Share by Needham

Dow Jones
·
10 Apr

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire
·
02 Apr

Elicio Therapeutics Names Preetam Shah CFO

MT Newswires Live
·
24 Mar

Elicio Therapeutics Hires CFO From Cidara Therapeutics

Dow Jones
·
24 Mar

Positive Buy Rating for Cidara Therapeutics Driven by Promising CD388 Development and Safety Profile

TIPRANKS
·
19 Mar